Chitosan nanoparticles loaded with aspirin and 5‐fluororacil enable synergistic antitumour activity through the modulation of NF‐κB/COX‐2 signalling pathway

Based on the enhancement of synergistic antitumour activity to treat cancer and the correlation between inflammation and carcinogenesis, the authors designed chitosan nanoparticles for co‐delivery of 5‐fluororacil (5‐Fu: an as anti‐cancer drug) and aspirin (a non‐steroidal anti‐inflammatory drug) and induced synergistic antitumour activity through the modulation of the nuclear factor kappa B (NF‐κB)/cyclooxygenase‐2 (COX‐2) signalling pathways. The results showed that aspirin at non‐cytotoxic concentrations synergistically sensitised hepatocellular carcinoma cells to 5‐Fu in vitro. It demonstrated that aspirin inhibited NF‐κB activation and suppressed NF‐κB regulated COX‐2 expression and prostaglandin E2 (PGE2) synthesis. Furthermore, the proposed results clearly indicated that the combination of 5‐Fu and aspirin by chitosan nanoparticles enhanced the intracellular concentration of drugs and exerted synergistic growth inhibition and apoptosis induction on hepatocellular carcinoma cells by suppressing NF‐κB activation and inhibition of expression of COX‐2.Inspec keywords: proteins, molecular biophysics, cellular biophysics, biomedical materials, cancer, nanoparticles, drug delivery systems, enzymes, tumours, nanomedicine, drugsOther keywords: chitosan nanoparticles, aspirin, 5‐fluororacil, synergistic antitumour activity, anticancer drug, nonsteroidal antiinflammatory drug, hepatocellular carcinoma cells, NF‐κB activation, NF‐κB regulated COX‐2 expression, PGE2, synergistic growth inhibition, apoptosis induction, prostaglandin E2 synthesis, intracellular concentration, noncytotoxic concentrations, NF‐κB‐cyclooxygenase‐2 signalling pathways, cyclooxygenase‐2, nuclear factor kappa B